Current Science

Open Access Open Access  Restricted Access Subscription Access

The Journey of the World’s First Non-Steroidal Contraceptive from Academic Venture to National Family Programme


Affiliations
1 Parasitology Division, CSIR-CDRI, Lucknow 226 031, India
2 Business Development- Intellectual Property Unit, CSIRCDRI, Lucknow 226 031, India
 

Globally, pharma companies are channelizing their investments mainly in lifestyle disorders (obesity, depression, hypertension, diabetes, respiratory disorders) and cancer for higher returns1,2. In recent years, though drug discovery for infectious diseases (especially viral and bacterial infections)3,4 has received considerable public–private investments, most parasitic diseases and fertility control remains less remunerative areas for investments1,2. These areas pose challenges for countries with inadequate access to life-saving and health-maintaining interventions. In the Indian context, our socio-economic structure has immensely affected investments in the health sector. Our total health expenditure and government’s contribution is significantly lagging behind other South- East Asian countries (Figure 1)5. A miniscule of this share is utilized for new drug discovery. Hence, it is unlikely that a private entity will step into financing and managing drug discovery R&D. Therefore, the government is expected to make necessary investments in new drug discoveries for affordable healthcare for the masses.
User
Notifications
Font Size

  • http://www.pharmafile.com/news/512401/22-pharma-companies-join-forces-global-non-communicable-disease-initiative

  • https://www.forbes.com/sites/johnlamatti na/2014/03/03/should-pharma-be-criticized-for-investing-too-much-in-fighting-cancer/# 54852ced1ff5

  • http://www.nasdaq.com/article/6-drug-stocks-in-focus-as-zika-virus-fear-spreads-cm674922

  • https://www.ft.com/content/8af200f0-54b4-11e6-9664-e0bdc13c3bef; https://data.worldbank.org/indicator/SH.XPD.TOTL.ZS (accessed on 17 October 2017).

  • https://www.wto.org/english/tratop_e/tpr_e/tp195_e.htm

  • http://indiabefore91.in/1991-economicreforms

  • https://thewire.in/168086/arteether-malaria-cdri-csir-research-funding/

  • Guidelines for Diagnosis and Treatment of Malaria in India, 2009; http://nvbdcp.gov.in/Doc/Guidelines_for_Diagnosis_Treatment.pdf

  • https://humdo.nhp.gov.in/new-contraceptives/

  • Nityanand, C., Ann. Natl. Acad. Med. Sci. (India), 1999, 35, 131–144.

  • Singh, M. M. and Kamboj, V. P., Biol. Reprod., 1981, 25, 171–180.

  • Blesson, C. S., Awasthi, S., Kharkwal, G., Daverey, A. and Dwivedi, A., Steroids, 2006, 71, 993–1000.

  • Jawahar, L., Contraception, 2010, 814, 275–280.

  • Nityanand, S. et al., In Current Concepts in Fertility Regulation and Reproduction (eds Puri, C. P. and Van Look, P. F. A.), Wiley Eastern Ltd., New Delhi, 1994, pp. 61–68.

  • http://www.lifecarehll.com/product/view/reference/698d51a19d8a121ce581499d7b701668hYCD

  • Arshad, M., Sengupta, S., Sharma, S., Ghosh, R., Sawlani, V. and Singh, M. M., J. Steroid Biochem. Mol. Biol., 2004, 91(1–2), 67–78.

  • Gara, R. K., Sundaram, V., Chauhan, S. C. and Jaggi, M., Curr. Med. Chem., 2013, 20, 4177–4184


Abstract Views: 610

PDF Views: 130




  • The Journey of the World’s First Non-Steroidal Contraceptive from Academic Venture to National Family Programme

Abstract Views: 610  |  PDF Views: 130

Authors

Niti Kumar
Parasitology Division, CSIR-CDRI, Lucknow 226 031, India
Garima Pant
Business Development- Intellectual Property Unit, CSIRCDRI, Lucknow 226 031, India
Sripathi Rao Kulkarni
Business Development- Intellectual Property Unit, CSIRCDRI, Lucknow 226 031, India

Abstract


Globally, pharma companies are channelizing their investments mainly in lifestyle disorders (obesity, depression, hypertension, diabetes, respiratory disorders) and cancer for higher returns1,2. In recent years, though drug discovery for infectious diseases (especially viral and bacterial infections)3,4 has received considerable public–private investments, most parasitic diseases and fertility control remains less remunerative areas for investments1,2. These areas pose challenges for countries with inadequate access to life-saving and health-maintaining interventions. In the Indian context, our socio-economic structure has immensely affected investments in the health sector. Our total health expenditure and government’s contribution is significantly lagging behind other South- East Asian countries (Figure 1)5. A miniscule of this share is utilized for new drug discovery. Hence, it is unlikely that a private entity will step into financing and managing drug discovery R&D. Therefore, the government is expected to make necessary investments in new drug discoveries for affordable healthcare for the masses.

References





DOI: https://doi.org/10.18520/cs%2Fv115%2Fi9%2F1638-1640